Rhodia intents to sell its pharmaceutical custom synthesis busines to Shasun Chemicals & Drugs
Jean-Pierre Clamadieu, Chief Executive Officer of Rhodia, said: "This transaction is in line with our announced strategy to refocus the Group's business portfolio and to find a solution for RPS (Rhodia Pharma Solutions). The transfer to Shasun will allow these activities to be pursued under optimum conditions for our customers."
Rhodia expects the transaction to be completed by the end of the 1st quarter of 2006, with the signature of the final contract, as well as the necessary official authorizations.
Most read news
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.